Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.91 USD | +3.85% | -8.36% | -25.13% |
May. 10 | UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating | MT |
May. 09 | Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 | MT |
Financials (USD)
Sales 2024 * | 115M | Sales 2025 * | 170M | Capitalization | 2.85B |
---|---|---|---|---|---|
Net income 2024 * | -344M | Net income 2025 * | -326M | EV / Sales 2024 * | 22.1 x |
Net cash position 2024 * | 305M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 15.8 x |
P/E ratio 2024 * |
-7.53
x | P/E ratio 2025 * |
-8.33
x | Employees | 525 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.52% |
Latest transcript on Arrowhead Pharmaceuticals, Inc.
1 day | +3.85% | ||
1 week | -8.36% | ||
Current month | +1.28% | ||
1 month | -7.25% | ||
3 months | -22.68% | ||
6 months | -16.39% | ||
Current year | -25.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 07-11-30 | |
Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.40% | 0 M€ | 0.00% | - | |
0.35% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 22.91 | +3.85% | 2,045,991 |
24-05-13 | 22.06 | -0.09% | 1,949,574 |
24-05-10 | 22.08 | -10.68% | 2,540,166 |
24-05-09 | 24.72 | -1.98% | 707,526 |
24-05-08 | 25.22 | +0.88% | 906,027 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.13% | 2.85B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- ARWR Stock